Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx). (February 2017) - Gullo, G.; Walsh, N.; Zacchia, A.; Hammond, L.; Fennelly, D.; Walshe, J.; O'Mahony, K.; Maltese, M.; Crown, J.